Systemic therapy represents the standard of care treatment for patients with advanced hepatocellular carcinoma (HCC). Given the increased risk of death from cirrhosis-related complications in patients ...

Background Inflammatory bowel diseases (IBDs) are characterised by dysbiosis and a leaky gut. The NADPH oxidase dual oxidase 2 (DUOX2) is upregulated in patients with IBD, yet its role in driving the ...

7 Institute of Anatomy and Cell Biology, Martin-Luther University Halle-Wittenberg, Halle, Germany 8 Institute of Anatomy, University of Leipzig, Leipzig, Germany Objective Bacterial translocation to ...

3 German Centre for Infection Research (Deutsches Zentrum für Infektionsforschung DZIF), Partner Site Hannover-Braunschweig, Hannover, Germany 4 Computational Biology for Individualised Medicine, ...

Objective Both the gut microbiome and host genetics are known to play significant roles in the pathogenesis of IBD. However, the interaction between these two factors and its implications in the ...

Professor M Trevisan, Department of Social and Preventive Medicine, School of Medicine and Biomedical Sciences, 270 Farber Hall, 3435 Main Street, Buffalo, New York 14214–3000, USA. Email: trevisan{at ...

Correspondence to Dr Daniela Sia, Division of Liver Diseases, Department of Medicine, Tisch Cancer Institute, Liver Cancer Program, Icahn School of Medicine at Mount Sinai, New York, New York, USA; ...

Correspondence to Professor Siew C Ng, Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, Hong Kong; siewchienng{at}cuhk.edu.hk; Dr Ruth Chan, Applied Biology and Chemical ...

Objective Hepatitis B virus (HBV) can integrate into the chromosomes of infected hepatocytes, contributing to the production of hepatitis B surface antigen (HBsAg) and to hepatocarcinogenesis. In this ...

Objective This study is to investigate the role of gut dysbiosis in triggering inflammation in the brain and its contribution to Alzheimer’s disease (AD) pathogenesis. Design We analysed the gut ...

Objectives Primary GI T-cell lymphoproliferative diseases (T-LPD) are heterogeneous entities, which raise difficult diagnosis and therapeutic challenges. We have recently provided evidences that ...